<DOC>
	<DOC>NCT00914901</DOC>
	<brief_summary>The purpose of the study is to assess the blood and urine concentrations of inhaled salmeterol.</brief_summary>
	<brief_title>Concentrations of Salmeterol in Blood and Urine</brief_title>
	<detailed_description>The purpose of the study is to assess the serum and urine concentrations of salmeterol after inhalation of 100 microgram salmeterol in one dose. Furthermore, to evaluate any difference in three groups: 10 healthy men, 10 male asthmatic subjects and 10 male elite athletes with asthma.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Physiciandiagnosed asthma with positive reversibility or challenge test. Informed consent. Age between 1845 years. Sex: male. Asthma classified as mild to moderate according to GINA guidelines. Used beta2agonist in minimum 12 months. Smokers or exsmokers with a smoking history of 10 pack years or more. Respiratory tract infections within the last 2 weeks prior to study day. Subjects with other chronic diseases than asthma and/or allergy. Allergy towards the study medicine. Use of beta2agonist 10 days prior to study day.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Doping</keyword>
	<keyword>Salmeterol</keyword>
	<keyword>Beta-agonist</keyword>
	<keyword>Urine concentrations</keyword>
</DOC>